Salivary gland carcinoma

Summary

Salivary gland carcinoma (MONDO:0000521) is a cancer (an umbrella term covering 13 Mondo subtypes) with 2 cohort genes (2 CIViC-evidence somatic drivers) and 113 clinical trials. Molecularly, AR OVEREXPRESSION confers sensitivity to Bicalutamide + Leuprolide in Salivary Gland Cancer (CIViC Level B); 6 further subtype–drug associations are mapped below. Top therapeutic interventions include lapatinib, cisplatin, and dasatinib anhydrous.

At a glance

• Classification: Cancer
• Umbrella term: 13 Mondo subtypes
• Cohort genes: 2
• Clinical trials: 113
• Precision-medicine evidence (CIViC): 7 subtype–drug associations

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	salivary gland carcinoma
Mondo ID	MONDO:0000521
DOID	DOID:0050904
NCIT	C9272
UMLS	C0948750
MedGen	215302
GARD	0027535
Anatomy (UBERON)	UBERON:0001044
Is cancer (heuristic)	yes

Also known as: carcinoma of saliva-secreting gland · carcinoma of salivary gland · carcinoma of the salivary gland · saliva-secreting gland carcinoma · salivary carcinoma · salivary gland cancer · salivary gland carcinoma

Data availability: 15 intOGen driver records.

Disease family

An umbrella term covering 13 Mondo subtypes.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system cancer › oral cavity cancer › salivary gland cancer › salivary gland carcinoma

Related subtypes (2): malignant tumor of minor salivary gland, major salivary gland cancer

Subtypes (13): salivary gland adenoid cystic carcinoma, major salivary gland carcinoma, salivary gland basal cell adenocarcinoma, salivary gland carcinoma ex pleomorphic adenoma, salivary gland large cell carcinoma, salivary gland small cell carcinoma, salivary gland epithelial myoepithelial carcinoma, salivary gland mucoepidermoid carcinoma, salivary gland squamous cell carcinoma, salivary duct carcinoma, minor salivary gland carcinoma, salivary gland mucinous adenocarcinoma, mammary analog secretory carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 6 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Somatic driver evidence (intOGen + CIViC, cohort fanout)

Gene	intOGen role	Cancer types	CIViC
ERBB2	Act	BLCA,BRCA,CESC,CHOL,COADREAD,EGC,ESCA,ESCC,LMS,LUAD,NSCLC,OVT,PRCC,READ,STAD,UCEC	CIViC #20
FDXR	Act	BRCA,CHOL,COAD,DLBCLNOS,GBC,GBM,LMS,NPC,NSCLC,PCM,PRAD,PROSTATE,STAD,STOMACH	CIViC #67

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
ERBB2	Orphanet:213726	Serous carcinoma of the corpus uteri
ERBB2	Orphanet:2800	Extramammary Paget disease
ERBB2	Orphanet:388	Hirschsprung disease
ERBB2	Orphanet:99976	Adenocarcinoma of the oesophagus and oesophagogastric junction
FDXR	Orphanet:542585	Auditory neuropathy-optic atrophy syndrome
FDXR	Orphanet:543470	Optic atrophy-ataxia-peripheral neuropathy-global developmental delay syndrome

Cohort genes → proteins

2 cohort genes, 2 distinct canonical proteins.

Evidence partition

Subset	Genes
civic_only	2

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
ERBB2	HGNC:3430	ENSG00000141736	P04626	Receptor tyrosine-protein kinase erbB-2	civic_evidence
FDXR	HGNC:3642	ENSG00000161513	P22570	NADPH:adrenodoxin oxidoreductase, mitochondrial	civic_evidence

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
ERBB2	Receptor tyrosine-protein kinase erbB-2	Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding.
FDXR	NADPH:adrenodoxin oxidoreductase, mitochondrial	Serves as the first electron transfer protein in all the mitochondrial P450 systems including cholesterol side chain cleavage in all steroidogenic tissues, steroid 11-beta hydroxylation in the adrenal cortex, 25-OH-vitamin D3-24 hydroxylat…

Protein-family classification

Druggable: 1 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.5

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Kinase	1	13.9×	0.142
Other/Unknown	1	0.9×	0.805

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
ERBB2	Kinase	yes	2.7.10.1	Rcpt_L-dom, Prot_kinase_dom, Ser-Thr/Tyr_kinase_cat_dom
FDXR	Other/Unknown	no		Ferredox_Rdtase_adrenod, FAD/NAD-bd_sf, Ferredox_Rdtase

Expression context

Cohort genes with no expression data: 0.

2 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	2
unknown	0

Top tissues across cohort

Tissue	Cohort genes
lower esophagus mucosa	1
right uterine tube	1
sural nerve	1
left adrenal gland cortex	1
right adrenal gland	1
right adrenal gland cortex	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
ERBB2	276	ubiquitous	marker	lower esophagus mucosa, right uterine tube, sural nerve
FDXR	208	ubiquitous	marker	right adrenal gland cortex, right adrenal gland, left adrenal gland cortex

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
ERBB2	9,659
FDXR	2,373

Structural data

PDB: 1 · AlphaFold-only: 1 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
ERBB2	P04626	63

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
FDXR	P22570	91.66

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 48. Enrichment computed across 2 evidence-associated genes (2 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
PLCG1 events in ERBB2 signaling	1	1427.5×	0.003	ERBB2
Electron transport from NADPH to Ferredoxin	1	1427.5×	0.003	FDXR
Drug-mediated inhibition of ERBB2 signaling	1	1427.5×	0.003	ERBB2
Resistance of ERBB2 KD mutants to trastuzumab	1	1427.5×	0.003	ERBB2
Resistance of ERBB2 KD mutants to sapitinib	1	1427.5×	0.003	ERBB2
Resistance of ERBB2 KD mutants to tesevatinib	1	1427.5×	0.003	ERBB2
Resistance of ERBB2 KD mutants to neratinib	1	1427.5×	0.003	ERBB2
Resistance of ERBB2 KD mutants to osimertinib	1	1427.5×	0.003	ERBB2
Resistance of ERBB2 KD mutants to afatinib	1	1427.5×	0.003	ERBB2
Resistance of ERBB2 KD mutants to AEE788	1	1427.5×	0.003	ERBB2
Resistance of ERBB2 KD mutants to lapatinib	1	1427.5×	0.003	ERBB2
Drug resistance in ERBB2 TMD/JMD mutants	1	1427.5×	0.003	ERBB2
Defective CYP11A1 causes AICSR	1	1142.0×	0.003	FDXR
GRB7 events in ERBB2 signaling	1	951.7×	0.004	ERBB2
Constitutive Signaling by Overexpressed ERBB2	1	475.8×	0.005	ERBB2
Metabolic disorders of biological oxidation enzymes	1	439.2×	0.005	FDXR
Downregulation of ERBB2:ERBB3 signaling	1	407.9×	0.005	ERBB2
Mitochondrial iron-sulfur cluster biogenesis	1	407.9×	0.005	FDXR
Pregnenolone biosynthesis	1	407.9×	0.005	FDXR
ERBB2 Activates PTK6 Signaling	1	407.9×	0.005	ERBB2
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors	1	380.7×	0.005	ERBB2
Developmental Lineage of Mammary Stem Cells	1	380.7×	0.005	ERBB2
Cytochrome P450 - arranged by substrate type	1	356.9×	0.005	FDXR
ERBB2 Regulates Cell Motility	1	356.9×	0.005	ERBB2
PI3K events in ERBB2 signaling	1	335.9×	0.005	ERBB2
Signaling by ERBB2 ECD mutants	1	335.9×	0.005	ERBB2
GRB2 events in ERBB2 signaling	1	317.2×	0.006	ERBB2
Sema4D induced cell migration and growth-cone collapse	1	285.5×	0.006	ERBB2
Developmental Lineage of Mammary Gland Myoepithelial Cells	1	271.9×	0.006	ERBB2
Metabolism of steroid hormones	1	259.6×	0.006	FDXR

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
immature T cell proliferation in thymus	1	1685.2×	0.009	ERBB2
negative regulation of immature T cell proliferation in thymus	1	1404.3×	0.009	ERBB2
ERBB2-ERBB4 signaling pathway	1	1404.3×	0.009	ERBB2
regulation of microtubule-based process	1	936.2×	0.009	ERBB2
ERBB2-ERBB3 signaling pathway	1	842.6×	0.009	ERBB2
ERBB2-EGFR signaling pathway	1	842.6×	0.009	ERBB2
enzyme-linked receptor protein signaling pathway	1	648.1×	0.009	ERBB2
Schwann cell development	1	526.6×	0.009	ERBB2
ubiquinone biosynthetic process	1	468.1×	0.009	FDXR
neurotransmitter receptor localization to postsynaptic specialization membrane	1	401.2×	0.009	ERBB2
motor neuron axon guidance	1	351.1×	0.009	ERBB2
positive regulation of MAP kinase activity	1	324.1×	0.009	ERBB2
positive regulation of transcription by RNA polymerase I	1	324.1×	0.009	ERBB2
steroid biosynthetic process	1	300.9×	0.009	FDXR
positive regulation of Rho protein signal transduction	1	290.6×	0.009	ERBB2
regulation of ERK1 and ERK2 cascade	1	290.6×	0.009	ERBB2
positive regulation of protein targeting to membrane	1	280.9×	0.009	ERBB2
neuromuscular junction development	1	263.3×	0.009	ERBB2
peptidyl-tyrosine phosphorylation	1	210.7×	0.010	ERBB2
regulation of angiogenesis	1	210.7×	0.010	ERBB2
oligodendrocyte differentiation	1	210.7×	0.010	ERBB2
semaphorin-plexin signaling pathway	1	200.6×	0.010	ERBB2
generation of precursor metabolites and energy	1	172.0×	0.011	FDXR
cellular response to growth factor stimulus	1	159.0×	0.011	ERBB2
cellular response to epidermal growth factor stimulus	1	159.0×	0.011	ERBB2
positive regulation of cell adhesion	1	135.9×	0.012	ERBB2
myelination	1	125.8×	0.012	ERBB2
epidermal growth factor receptor signaling pathway	1	123.9×	0.012	ERBB2
positive regulation of epithelial cell proliferation	1	122.1×	0.012	ERBB2
wound healing	1	113.9×	0.012	ERBB2

Therapeutics

Drug target analysis

Approved (phase 4): 1 · Phase ≥3: 1 · Phased (≥1): 1 · Undrugged: 1

Druggability breadth: 1 of 2 evidence-associated genes (50%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
ERBB2	CLOTRIMAZOLE

Top cohort targets by molecule count

Symbol	Molecules	Max phase
ERBB2	83	4
FDXR	0	0

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
CLOTRIMAZOLE	4	ERBB2
ERLOTINIB HYDROCHLORIDE	4	ERBB2
PONATINIB	4	ERBB2
AFATINIB	4	ERBB2
LAPATINIB DITOSYLATE	4	ERBB2
SORAFENIB	4	ERBB2
NERATINIB	4	ERBB2
IBRUTINIB	4	ERBB2
AFATINIB DIMALEATE	4	ERBB2
CABOZANTINIB	4	ERBB2
DACOMITINIB	4	ERBB2
DACOMITINIB ANHYDROUS	4	ERBB2
VANDETANIB	4	ERBB2
TRIBROMSALAN	4	ERBB2
BOSUTINIB	4	ERBB2
BITHIONOL	4	ERBB2
ASTEMIZOLE	4	ERBB2
EBASTINE	4	ERBB2
OSIMERTINIB	4	ERBB2
BRIGATINIB	4	ERBB2
ACALABRUTINIB	4	ERBB2
ZANUBRUTINIB	4	ERBB2
TUCATINIB	4	ERBB2
TIRABRUTINIB	4	ERBB2
PACLITAXEL	4	ERBB2
LAZERTINIB	4	ERBB2
HEXACHLOROPHENE	4	ERBB2
DOXORUBICIN	4	ERBB2
DASATINIB	4	ERBB2
ERLOTINIB	4	ERBB2

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
ERBB2	1,221	Binding:1136, Functional:79, ADMET:6

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
ERBB2	2.7.10.1	receptor protein-tyrosine kinase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
ERBB2	1,221

Pharmacogenomics

Cohort genes with a PharmGKB record: 2; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Drug repurposing candidates

28 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.

Compound	Max phase	Cohort target (bioactivity)
CLOTRIMAZOLE	4	ERBB2
PONATINIB	4	ERBB2
AFATINIB	4	ERBB2
LAPATINIB DITOSYLATE	4	ERBB2
NERATINIB	4	ERBB2
IBRUTINIB	4	ERBB2
AFATINIB DIMALEATE	4	ERBB2
CABOZANTINIB	4	ERBB2
DACOMITINIB	4	ERBB2
DACOMITINIB ANHYDROUS	4	ERBB2
VANDETANIB	4	ERBB2
TRIBROMSALAN	4	ERBB2
BOSUTINIB	4	ERBB2
BITHIONOL	4	ERBB2
ASTEMIZOLE	4	ERBB2
EBASTINE	4	ERBB2
OSIMERTINIB	4	ERBB2
BRIGATINIB	4	ERBB2
ACALABRUTINIB	4	ERBB2
ZANUBRUTINIB	4	ERBB2
TUCATINIB	4	ERBB2
TIRABRUTINIB	4	ERBB2
PACLITAXEL	4	ERBB2
LAZERTINIB	4	ERBB2
HEXACHLOROPHENE	4	ERBB2
DOXORUBICIN	4	ERBB2
DASATINIB	4	ERBB2
ERLOTINIB	4	ERBB2

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	1	ERBB2
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	1	FDXR

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
FDXR	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 113.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	54
PHASE1	24
Not specified	18
PHASE1/PHASE2	13
PHASE3	2
PHASE4	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01344356	PHASE4	COMPLETED	Stereotactic Body Radiotherapy for Head and Neck Tumors
NCT00588770	PHASE3	ACTIVE_NOT_RECRUITING	Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT02048254	PHASE3	UNKNOWN	Study of I-125 Brachytherapy Versus Intensity-modulated Radiation Therapy to Treat Inoperable Salivary Gland Cancer
NCT02568267	PHASE2	ACTIVE_NOT_RECRUITING	Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
NCT02628067	PHASE2	ACTIVE_NOT_RECRUITING	Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
NCT03360890	PHASE2	ACTIVE_NOT_RECRUITING	Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors
NCT03556228	PHASE1/PHASE2	RECRUITING	VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
NCT03781986	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	APG-115 in Salivary Gland Cancer Trial
NCT03942653	PHASE2	RECRUITING	Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma
NCT04140526	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
NCT04209660	PHASE2	ACTIVE_NOT_RECRUITING	Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
NCT04620187	PHASE2	RECRUITING	Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
NCT04895735	PHASE2	ACTIVE_NOT_RECRUITING	MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer
NCT05010629	PHASE2	ACTIVE_NOT_RECRUITING	9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
NCT05074940	PHASE2	ACTIVE_NOT_RECRUITING	Amivantamab in Adenoid Cystic Carcinoma
NCT05075980	PHASE2	ACTIVE_NOT_RECRUITING	Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study
NCT05408845	PHASE2	RECRUITING	Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
NCT05669664	PHASE2	ACTIVE_NOT_RECRUITING	Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers
NCT05884320	PHASE2	RECRUITING	Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Secretory Gland Cancers
NCT05898373	PHASE1/PHASE2	NOT_YET_RECRUITING	Vedicitumomab Alone or in Combination for the Treatment of Locally Advanced or Metastatic SDC
NCT05924256	PHASE2	ACTIVE_NOT_RECRUITING	A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing
NCT06145308	PHASE2	RECRUITING	Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
NCT06695845	PHASE2	RECRUITING	A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
NCT06805617	PHASE2	RECRUITING	A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers
NCT06923826	PHASE2	RECRUITING	Sacituzumab Govitecan in Metastatic Salivary Gland and Thyroid Cancers (SG-SGTC)
NCT07464366	PHASE2	RECRUITING	The Safety and Efficacy of MRG003 With or Without Putrelimab in Recurrent or Metastatic Salivary Gland Cancer: a Single-center, Open-label Cohort Study
NCT00033618	PHASE2	COMPLETED	Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck
NCT00055770	PHASE1/PHASE2	COMPLETED	Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer
NCT00077428	PHASE2	COMPLETED	Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck
NCT00095563	PHASE2	COMPLETED	Lapatinib in Treating Patients With Recurrent and/or Metastatic Adenoid Cystic Cancer or Other Salivary Gland Cancers
NCT00095628	PHASE2	COMPLETED	SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT00096512	PHASE2	COMPLETED	S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT00101348	PHASE1/PHASE2	COMPLETED	Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
NCT00114283	PHASE2	COMPLETED	Lapatinib Ditosylate in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
NCT00126607	PHASE2	TERMINATED	Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer
NCT00458978	PHASE2	COMPLETED	Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer
NCT00492089	PHASE2	COMPLETED	Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
NCT00507767	PHASE2	COMPLETED	Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
NCT00509002	PHASE2	COMPLETED	Iressa Study in Patients With Salivary Gland Cancer
NCT00859937	PHASE2	COMPLETED	Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
LAPATINIB	4	6
CISPLATIN	4	5
DASATINIB ANHYDROUS	4	4
SORAFENIB	4	4
ERLOTINIB HYDROCHLORIDE	4	2
AXITINIB	4	1
BICALUTAMIDE	4	1
ENTRECTINIB	4	1
ERIBULIN MESYLATE	4	1
IXABEPILONE	4	1
TALAZOPARIB	4	1
TEMSIROLIMUS	4	1
TRIPTORELIN	4	1
VORINOSTAT	4	1
CEDIRANIB MALEATE	3	1
DOVITINIB	3	1
ISPINESIB	2	1
CHEMBL4583196	0	2
CHEMBL2326523	0	1
CHEMBL275117	0	1
CHEMBL4517714	0	1
CHEMBL5405436	0	1
CHEMBL4578973	0	1
(R)-BICALUTAMIDE	0	1

Precision-medicine subtype map (CIViC)

Drug × molecular subtype: 7 predictive associations from 7 curated evidence items.

Molecular subtype	Therapy	Effect	Level	CIViC
AR OVEREXPRESSION	Bicalutamide + Leuprolide	Sensitivity/Response	CIViC B	EID6953
ERBB2 Amplification	Pertuzumab + Trastuzumab	Sensitivity/Response	CIViC B	EID5984
ERBB2 Amplification	Trastuzumab Emtansine	Sensitivity/Response	CIViC B	EID7856
ERBB2 Overexpression	Trastuzumab + Docetaxel	Sensitivity/Response	CIViC B	EID7078
ERBB2 Overexpression	Paclitaxel + Trastuzumab	Sensitivity/Response	CIViC C	EID6170
ERBB2 Overexpression	Trastuzumab + Capecitabine + Zoledronic Acid	Sensitivity/Response	CIViC C	EID6171
AR AR-V7	Abiraterone Acetate	Resistance	CIViC C	EID6954